Confo Therapeutics

Please note: The information displayed on this page might be outdated.
Confo Therapeutics: Developer of a drug discovery technology designed to address unmet medical needs. The company is building a portfolio of programs based on its proprietary technology which derives specialized camelid single-domain antibodies which stabilize G-protein coupled receptors (GPCRs) in a conformation of interest for drug discovery, enabling the medical industry to be provided with novel pathway-selective agonists for improved therapeutic intervention.

A private Company, Confo is backed by an international investor syndicate: BioGeneration Ventures, Capricorn Venture Partners, Fund+, MINTS, Perceptive Advisors, PMV, QBIC, V-Bio Ventures, VIB and Wellington Partners. Confo has raised a total of c. €40.3 million (both dilutive and non-dilutive funding) since it was spun out of Vrije Universiteit Brussel and VIB in 2015. The Company is headquartered in Ghent, Belgium and has laboratory facilities in Brussels (ConfobodyTM discovery), as well as Ghent (Drug Discovery).
Based in...
Clinical Stage
Pre-Clinical Stage
Disease Space
Central Nervous System, Rare Disease
Europe, Private
Therapeutic Modalities
Platform Technology, Small Molecule
Technologiepark 94
Zwijnaarde, 9052

Company Participants at Winter Private Company Showcase

Cedric Ververken
Confo Therapeutics, CEO
Cedric Ververken (ir.Ph.D.) - CEO, joined Confo Therapeutics in October 2016 from Ablynx NV where he was Vice President Business Development and played a key role in landmark deals for Ablynx. Prior to moving to business development he worked through various R&D functions at Ablynx, first as a scientist in the pharmacology group and later as project manager, leading cross-functional project teams from discovery up to Phase II clinical studies. He therefore brings over 10 years of R&D and business development experience to valorize Confo Therapeutics’ assets and technology.​

Upcoming Company Event Participation